1. Introduction {#sec1}
===============

Depression is a debilitating and highly prevalent psychiatric disorder characterised primarily by a depressed mood, loss of interest or pleasure in everyday activities and significant changes in weight or appetite ([@bib1]). Behind HIV/AIDS, depression is the second largest contributor to the global burden of disease and is predicted to maintain that position through to 2030 ([@bib47]). Despite this, the etiology of depression remains to be adequately elucidated. Several reasons have contributed to this lack of understanding, including that depression is a complex, heterogeneous disorder with multiple factors contributing to its development ([@bib5]; [@bib35]). Furthermore, due to the subjective nature of depression, aspects of its symptomatology have proven challenging to replicate in animal models of the disorder ([@bib9]; [@bib35]; [@bib55]). The improvement of animal models is therefore an essential step towards advancing the understanding of the neurobiology of depression and the development of effective treatments. For an animal model to be considered valid the symptoms induced must be reasonably analogous to those observed in humans (face validity), the treatments effective in humans must also be effective in the animal model (predictive validity) and the model and human disease should have identical causative factors (construct validity) ([@bib51]; [@bib73]). Several rodent models of depression have been developed over the past few decades including chronic mild stress (CMS) ([@bib81]), olfactory bulbectomy ([@bib24]), maternal deprivation ([@bib37]; [@bib46]; [@bib71]) and chronic restraint stress paradigms ([@bib7]; [@bib68]). However, many of these models either fail to reproduce some of the core symptoms of depression, do not satisfy the aforementioned requirements for a valid animal model, or suffer from poor cross-reliability between laboratories.

An emerging class of animal models of depression utilise psychosocial stress paradigms comprising repeated social defeats. Social defeat models involve placing an animal into the home cage of an aggressive resident, enabling physical defeat and subordination from the defeated animal. Such models have demonstrated central aspects of face, predictive and construct validity ([@bib6]; [@bib77]) whereby treatment with clinical antidepressants reversed behavioural and physiological effects induced by the model. Depending on the model, mice may be exposed to the resident aggressor for periods of up to between 10 min (for a detailed protocol see [@bib19]) and 2 h ([@bib70]). This increases the opportunity for fight wounds to develop (see [@bib19]; and [@bib70]) which potentially contribute pain and inflammation to the psychosocial stress ([@bib61]). The social defeat/overcrowding (SD/OC) model is an alternative protocol, where mice are separated by barriers following the initial defeat, therefore reducing the opportunity for injuries to occur, and are also intermittently subjected to unpredictable periods of overcrowding with other defeated mice ([@bib13], [@bib14]; [@bib66]; [@bib76]). Studies utilising this model have demonstrated increased social avoidance in the social interaction test (SIT), increased immobility time in the forced swim test (FST), anxiety-like behaviour in the light-dark box test (LDB) as well as alterations in body weight, protein levels, gene expression and other physiological functions ([@bib13], [@bib14]; [@bib66]; [@bib76]). However, results across laboratories have been varied, calling in to question the reproducibility of the model. Additionally, the predictive validity of this model has yet to be ascertained. Further characterisation of this model using a clinically effective antidepressant would be a crucial step towards its more widespread use in preclinical depression research.

To this end, we aimed to further characterise the SD/OC model in male C57BL/6JArc mice, including analyses of behaviour during SD sessions and a battery of behavioural tests for depression and/or anxiety-like behaviours at the conclusion of the SD/OC protocol. We also aimed to assess the effects of the clinically effective antidepressant fluoxetine, and the potential antidepressant properties of Cu^II^(atsm), in the SD/OC model. Cu^II^(atsm) is a member of the bis(thiosemicarbazone) (BTSC) class of compounds. BTSCs are stable, low molecular weight compounds capable of crossing cell membranes including the blood-brain barrier (BBB) ([@bib15]). BTSCs show therapeutic potential in neurodegenerative diseases ([@bib27]; [@bib32]; [@bib67]) via mechanisms that include the scavenging of the highly reactive nitrogen free radical, peroxynitrite (reviewed in [@bib50]). Recent evidence suggests that depression is associated with neuroinflammatory and oxidative/nitrosative stress mechanisms ([@bib23]; [@bib26]; [@bib28]; [@bib44], [@bib43]; [@bib62]). Targeting nitrosative stress has also previously been demonstrated to have antidepressant effects in animal models ([@bib11]; [@bib25]; [@bib59]). We therefore sought to assess Cu^II^(atsm) in the SD/OC model due to its anti-neuroinflammatory and anti-nitrosative stress properties.

2. Materials and methods {#sec2}
========================

2.1. Animals {#sec2.1}
------------

Two separate trials were conducted using male C57BL/6JArc mice (Trial 1: n = 48, 10 weeks of age; Trial 2: n = 40, 9 weeks of age). Mice of various strains (SJL (48% of total bouts fought), Swiss (23%), SJL/BL6 (15%), C57BL/6 (6%), CD1 (5%), Sv129 (3%)) and age (9--52 weeks of age) were used as resident aggressors in Trial 1. In Trial 2 aggressor mice used were almost exclusively of the SJL strain (92%; 17--24 weeks of age). All mice were purchased from Animal Resources Centre (C57BL/6JArc, SJL; Canning Vale, WA, Australia) or bred in-house at The Florey Institute of Neuroscience (Melbourne, Victoria, Australia). All mice involved in the study were single housed for at least one week prior to commencement of their respective trials and remained single housed for the duration of the experiment (except during the overcrowding procedures). Experimental mice were housed in standard open top cages (26.5 × 14 × 12 cm) and aggressor mice in standard transparent cages (29.5 × 16 × 13 cm), both with sawdust bedding and tissue paper nesting material. The holding room was temperature controlled (18.5 ± 1 °C) and under a 12 h light/dark cycle (lights on at 0700 h). Standard rodent food and water was available *ad libitum*. All experimentation was performed in accordance with the Prevention of Cruelty to Animals Act (2004), under the guidelines of the National Health and Medical Research Council Code of Practice for the Care and Use of Animals for Experimental Purposes in Australia (2013) and approved by The Florey Animal Ethics Committee (AEC number: 15--020). All efforts were made to minimise animal suffering.

2.2. Social defeat/overcrowding (SD/OC) protocol {#sec2.2}
------------------------------------------------

The SD/OC protocol was carried out as previously described ([@bib13], [@bib14]; [@bib66]). All aggressor mice were screened for aggressive behaviour on at least three individual days prior to the first day of experiments. The mice were exposed to a test C57BL/6 intruder until the first attack followed by defeat posture ([Fig. 1](#fig1){ref-type="fig"}) ([@bib54]), or for a maximum of 10 min. Mice displaying the shortest attack latencies were chosen as aggressors for the trials. Experimental C57BL/6JArc mice were randomly assigned to one of four groups: 1. No SD/OC and treated with vehicle (Control (Con)), 2. Exposed to SD/OC and treated with vehicle (Veh), 3. SD/OC with fluoxetine treatment (Fluox) or 4. SD/OC with Cu^II^(atsm) treatment (Cu(atsm)) (Trial 1: n = 12; Trial 2: n = 10 per group). Control mice remained undisturbed except for daily oral gavaging. SD/OC mice were exposed to a 19 day unpredictable stress protocol consisting of social defeat (SD) and overcrowding (OC) sessions ([Fig. 2](#fig2){ref-type="fig"}). SD sessions were carried out once (on days 1, 2, 4--7, 9, 12 and 19) or twice (on days 8 and 16) per day. Experimental mice never encountered the same aggressor mouse more than once. Aggressors were ranked according to latency to attack and pseudorandomly assigned to ensure a balanced and consistent presentation of aggression. SD sessions consisted of placing the experimental mouse into the home cage of the aggressor and allowing interaction until defeat posture/s were displayed by the experimental mouse ([Fig. 1](#fig1){ref-type="fig"}). The mice were then separated by a wire mesh barrier for 2 h to allow visual, auditory and olfactory, but not physical contact. After 2 h the barrier was removed and another bout and defeat was allowed to take place. The thirteen SD sessions were thus comprised of two SD bouts each, resulting in a total of 26 SD bouts across the protocol. The number of defeat postures displayed was measured for each of these 26 SD bouts. In Trial 1, SD bouts were terminated following one defeat posture regardless of whether an attack occurred or not. In Trial 2, SD bouts were terminated following at least five defeat postures and definitive attack behaviour from the aggressor. If attacks were particularly ferocious and containing extensive biting behaviour by the aggressor, the SD bout was terminated early. All SD bouts were filmed (side-on, four cages at a time) using a standard video camera. Number and latency of defeat posture and latency to attack in Trial 2 were quantified from video recordings. For the overcrowding protocol all mice from one treatment group were housed together in a standard transparent cage for 24 or 48 h with free access to food and water. No injuries were observed in any of the overcrowded mice. Overcrowding occurred on days 3--4, 10--11, 13--15 and 17--18 ([Fig. 2](#fig2){ref-type="fig"}).Fig. 1**Mouse defeat posture.**An experimental C57BL/6JArc mouse in characteristic defeat posture.Fig. 1Fig. 2**Experimental timeline.**Experimental timeline showing the 19 day SD/OC protocol comprised of repeated social defeats and overcrowding procedures, followed by 6 days of behavioural analysis.Fig. 2

2.3. Drugs {#sec2.3}
----------

Fluoxetine (Cat No. PHR1394, Sigma Aldrich) or Cu^II^(atsm) (prepared in-house according to [@bib17]) were administered daily at a dose of 20 mg/kg ([@bib56]) and 30 mg/kg ([@bib27]), respectively. Standard suspension vehicle (SSV; 0.9% Na-carboxymethylcellulose, 0.5% benzyl alcohol, 0.5% Tween 80^®^, 0.4% sodium chloride) was used as a vehicle. All drugs were prepared fresh daily and administered by oral gavage at a volume of 4 ml/kg. Gavage was performed daily throughout the SD/OC and behavioural testing period, a total duration of four weeks, in order to encompass both the manifestation of any depression-like changes and the onset of antidepressant action.

2.4. Body weights {#sec2.4}
-----------------

All mice were weighed daily prior to gavage sessions. Fluctuations in weight were measured by calculating the difference in weight as a percentage of the initial weight on day 1, or the percentage change from the initial weight for a specified period (Day 1--19, 20--26, 1--26; pre OC-post OC).

2.5. Behavioural analysis {#sec2.5}
-------------------------

Following the conclusion of the SD/OC model all mice underwent a battery of behavioural tests ([Fig. 2](#fig2){ref-type="fig"}). All mice were habituated to the respective behavioural assessment rooms for at least 1 h prior to any behavioural test. With the exception of the saccharin preference test (SPT), which was conducted over a 48 h period, all behavioural testing was conducted between 0900 and 1630 h.

### 2.5.1. Social interaction test (SIT) {#sec2.5.1}

To investigate the influence of the SD/OC model on social avoidance behaviour, the SIT was conducted on the day following the final social defeat. The SIT was carried out as previously described ([@bib13], [@bib14]). The experimental mouse was placed into a plastic box (29.5 × 35.5 × 22.5 cm) containing an empty ('no target') wire mesh cage (9 × 9 x 10.5 cm) positioned against the wall and allowed to explore for 2.5 min. The mouse was returned to its home cage for 1 min, while an unfamiliar mouse ('target') was placed inside the wire mesh cage. 'Target' mice were SD-naïve males of the Swiss strain in Trial 1 and a SJL in Trial 2. The experimental mouse was then placed into the box and allowed to explore for another 2.5 min. The equipment was cleaned with 80% ethanol and dried between trials. All testing was conducted under red light to reduce interference of general anxiety-like behaviour with social interaction behaviour. All trials were recorded via cameras mounted on the ceiling above the box and evaluated using Top Scan Lite software (Clever Sys, Inc.). Social avoidance behaviour was assessed by measuring the time spent in the interaction zone (IZ) (5 cm wide area around the wire mesh cage) and calculating an interaction ratio (time spent in IZ with 'target' present \[s\]/time spent in IZ with 'no target' present \[s\]). An interaction ratio of less than one was considered indicative of social avoidance behaviour.

### 2.5.2. Locomotor activity (LMA) {#sec2.5.2}

LMA in an open field was assessed by placing mice individually into the locomotor cell (27.3 × 27.3 × 20 cm) and activity monitored for 15 min by a grid of infrared beams. All locomotor cells were cleaned with 80% ethanol and dried between each trial. The data were analysed using Activity Monitor Version 6.02 software (Med Associates, Inc).

### 2.5.3. Light-dark box test (LDB) {#sec2.5.3}

The influence of the SD/OC model on anxiety-related behaviour was examined in the LDB. The LDB was carried out as previously described ([@bib12], [@bib13]). The LDB was conducted using the locomotor activity cell with a dark compartment insert (13.3 × 26.6 × 18.8 cm) covering half the floor area and a lamp positioned over the light half (934--999 lux). Mice were placed inside the dark compartment facing away from the access door (small archway, 5.3 × 6.6 cm). The duration of the test was 10 min and activity was measured by a grid of infrared beams. The locomotor cell and dark box insert were cleaned with 80% ethanol and dried between trials. The data were analysed using Activity Monitor Version 6.02 software (Med Associates, Inc). The number of transitions between compartments and the time spent in the light side was recorded.

### 2.5.4. Saccharin preference test (SPT) {#sec2.5.4}

The SPT was used to assess aspects of anhedonia. Mice were habituated to drinking from 15 ml Falcon tubes with the tips cut off for several days prior to the testing. Upon testing, mice were presented with two 15 ml Falcon tubes, one containing tap water and the other 0.1% (w/v) saccharin (Merck Millipore), for a period of 48 h. The position of the tubes was exchanged after 24 h to avoid the development of side bias. All tubes were weighed at the 0, 24 and 48 h time points. Saccharin preference was calculated as the weight of saccharin consumed as a percentage of the total fluid (saccharin + water) consumption.

### 2.5.5. Forced swim test (FST) {#sec2.5.5}

The FST was used to evaluate behavioural despair/learned helplessness. The FST was carried out as previously described ([@bib14]; [@bib60]). 2 L glass beakers were filled with approximately 1.8 L (14 cm) of water (25 ± 0.5 °C) and mice were individually placed into the water for 6 min. The water was changed between each trial. Behaviour was recorded by a video camera positioned side on to the beaker and analysed using Forced Swim Version 2.00 software (Clever Sys, Inc.). The duration of immobility was recorded during the last 4 min of the 6 min test.

2.6. Statistical analysis {#sec2.6}
-------------------------

Statistical analyses were performed using the software packages GraphPad Prism (Version 7.02 for windows) or SigmaPlot 12.0. Comparisons between respective 'target' and 'no target' trials in the SIT were analysed using Student\'s paired *t*-test. The body weights were averaged over two day blocks in order to meet the assumptions for parametric testing and analysed using two-way repeated measures analysis of variance (ANOVA), followed by Tukey\'s post hoc multiple comparisons test. The number of defeat postures displayed and latency to defeat postures were log~10~ transformed in order to meet the assumptions for parametric testing and analysed using two-way repeated measures ANOVA followed by Tukey\'s post hoc multiple comparisons test. Latency to attack data did not meet assumptions for parametric testing and were therefore analysed within each SD session using Wilcoxon Signed Rank tests. One aggressor in session one and four on session two were excluded from this analysis since they were not used in both the pre- and post-barrier bouts in these sessions. All other data were analysed using a one-way ANOVA followed by Tukey\'s post hoc tests. For all analyses, P \< 0.05 was considered to be statistically significant. Except for [Fig. 5](#fig5){ref-type="fig"}A where medians and 95% confidence intervals (CI) are presented, all data are presented as the mean ± SEM.Fig. 3**Social defeats elicited with or without an attack.**(**A**) Distribution of social defeats in Trial 1 where no attack or an attack occurred and (**B**) the strain of aggressor eliciting the no attack social defeats.Fig. 3Fig. 4**Effects of SD/OC on the number of defeat postures displayed.**The number of social defeats displayed per (**A**) overall treatment group and (**B**) across time during Trial 2. Data are means ± SEM. n = 10. ^\#^P \< 0.05 vs. Veh; ^†^P \< 0.05, ^††^P \< 0.01, ^†††^P \< 0.001 vs. Fluox for respective social defeat number, by two-way repeated measures ANOVA with Tukey\'s post hoc tests on log~10~ transformed data.Fig. 4Fig. 5**Effects of SD/OC on the latencies to attack by residents and to display defeat posture by intruders.**(**A**) Latency to attack by residents and (**B**) latency to display defeat posture by intruders in Trial 2. n = 30. In (**A**) data are medians ± 95% CI; ^†^P \< 0.05, ^††^P \< 0.01 for pre- versus post-barrier bouts within session by Wilcoxon Signed Rank test. In (**B**) data are means ± SEM; ^∗^P \< 0.05, ^∗∗^P \< 0.01, ^∗∗∗^P \< 0.001 between SD sessions; ^\#\#\#^P \< 0.001 for main effect of pre- versus post-barrier bouts exposure to resident, by two-way repeated measures ANOVA on log~10~ transformed data.Fig. 5

3. Results {#sec3}
==========

3.1. Social defeat sessions {#sec3.1}
---------------------------

In Trial 1 a substantial number of mice displayed defeat posture without the need to be physically attacked, but rather displayed defeat posture as soon as the aggressor came in close proximity ([Fig. 3](#fig3){ref-type="fig"}A). The majority of the SDs presented without an attack were perpetrated by Swiss or CD1 mice ([Fig. 3](#fig3){ref-type="fig"}B). SJL mice were observed to be the most reliably aggressive strain and were selected as the predominant aggressors for Trial 2. In Trial 2, SDs were aimed to be terminated following five defeat postures ([Fig. 4](#fig4){ref-type="fig"}) and definitive attack behaviour by the aggressor. However, variation in the number of defeat postures displayed occurred due to early termination of SD bouts (as a result of overly ferocious attacks) and the speed of defeat posture presentation.

Two-way repeated measures ANOVA revealed that the number of defeat postures displayed was augmented with increasing number of SD bouts, with a significant interaction between SD bout and drug treatment observed (Treatment: F~(2,27)~ = 1.631, P = 0.2144; SD bout number: F~(25,675)~ = 11.06, P \< 0.001; interaction: F~(50,675)~ = 1.491, P = 0.0179; [Fig. 4](#fig4){ref-type="fig"}B). Post hoc analysis revealed a significant decrease in the number of defeat postures in the fluoxetine treated mice versus vehicle for SD bouts 13, 14 and 26 (P \< 0.05; [Fig. 4](#fig4){ref-type="fig"}B) and also a decrease in defeat postures in fluoxetine treated mice compared to Cu^II^(atsm) treated mice for SD sessions 11 (P \< 0.05), 13 (P \< 0.001) and 23 (P \< 0.01; [Fig. 4](#fig4){ref-type="fig"}B).

Median attack latency by resident aggressors in Trial 2 was approximately stable across the thirteen SD sessions, with a shorter latency to attack demonstrated in post- compared with pre-barrier bouts, depending on SD session (n = 30 for all sessions: Session 1, Z = −2.055, P \< 0.05; Session 3, Z = −3.138, P \< 0.01; Session 4, Z = −3.045, P \< 0.01; Session 5, Z = −1.823, P \< 0.1; Session 7, Z = −2.37, P \< 0.05; Session 8, Z = −1.903, P \< 0.1; Session 10: Z = −2.14, P \< 0.05; [Fig. 5](#fig5){ref-type="fig"}A).

The latency to present defeat posture reduced with increasing numbers of SD sessions, particularly in the latter of the two SD bouts ("post-barrier") within a session (Session: F~(12,346)~ = 25.525, P \< 0.001; pre/post barrier: F~(1,346)~ = 105.954, P \< 0.001; interaction: F~(12,346)~ = 1.225, P = 0.264; [Fig. 5](#fig5){ref-type="fig"}B), but was not affected by treatment (Treatment: F~(2,673)~ = 0.224, P = 0.801; SD session: F~(25,673)~ = 15.587, P \< 0.001; interaction: F~(50,\ 673)~ = 0.846, P = 0.767; data not shown). Note: data from two mice were excluded from the latency analyses: one vehicle-treated mouse in SD bout two which had a latency to defeat posture of 474 s; the other mouse (fluoxetine treatment, SD bout 17) because it did not show a defeat posture before termination of the fight bout due to excessive aggression.

3.2. Body weight {#sec3.2}
----------------

The SD/OC model influenced body weight and was modulated by drug treatment over time (Trial 1: treatment: F~(3,43)~ = 8.18, P = 0.0002; time: F~(12,\ 516)~ = 52.29, P \< 0.001; interaction: F~(36,\ 516)~ = 9.833, P \< 0.001; [Fig. 6](#fig6){ref-type="fig"}A; Trial 2: treatment: F~(3,\ 36)~ = 5.267, P = 0.0041; time: F~(12,\ 432)~ = 179.0, P \< 0.001; interaction: F~(36,\ 432)~ = 8.972, P \< 0.001; [Fig. 6](#fig6){ref-type="fig"}B).Fig. 6**Effects of SD/OC on body weight across time**.Percentage change in body weight in (**A**) Trial 1 and (**B**) Trial 2. Arrowheads represent the end of the SD/OC component of the protocol. Body weights were averaged over two days per time block in order to meet the assumptions for parametric testing. Data are means ± SEM. n = 10--12. ^∗^P ≤ 0.05, ^∗∗^P ≤ 0.01, ^∗∗∗^P ≤ 0.001 vs. Con; ^\#^P ≤ 0.05, ^\#\#^P ≤ 0.01, ^\#\#\#^P ≤ 0.001 vs. Veh within time blocks, by two-way repeated measures ANOVA with Tukey\'s post hoc tests.Fig. 6

SD/OC -- Vehicle treated mice exhibited significant weight gain relative to control mice ([Fig. 6](#fig6){ref-type="fig"}). In Trial 1 SD/OC -- Vehicle treated mice exhibited an increased body weight gain compared to non-SD controls during SD/OC exposure (F~(3,\ 43)~ = 9.405, P \< 0.05; [Fig. 7](#fig7){ref-type="fig"}A), following conclusion of the SD/OC component during behavioural testing (F~(3,\ 43)~ = 11.73, P \< 0.001; [Fig. 7](#fig7){ref-type="fig"}B) and throughout the entire trial (F~(3,\ 43)~ = 18.08, P \< 0.001; [Fig. 7](#fig7){ref-type="fig"}C). In Trial 2 weight gain in SD/OC -- Vehicle treated mice did not differ significantly from controls during SD/OC exposure ([Fig. 7](#fig7){ref-type="fig"}D) however, increased weight gain compared to controls was observed following conclusion of the SD/OC component during behavioural testing (F~(3,\ 36)~ = 6.23, P \< 0.01; [Fig. 7](#fig7){ref-type="fig"}E) and throughout the entire trial (F~(3,\ 36)~ = 9.465, P \< 0.001; [Fig. 7](#fig7){ref-type="fig"}F).Fig. 7**Effects of SD/OC on body weight during specific testing components**.Percentage change in body weight in (**A, B, C**) Trial 1 and (**D, E, F**) Trial 2. (**A, D**) The change in weight per day was calculated for the SD/OC component (day 1--19), (**B, E**) the period following the SD/OC component during behaviour testing (day 20--26) and (**C, F**) the entire duration of the protocol (day 1--26). Data are means ± SEM. n = 10--12. ^∗^P ≤ 0.05, ^∗∗^P ≤ 0.01, ^∗∗∗^P ≤ 0.001 vs. Con; ^\#\#^P ≤ 0.01, ^\#\#\#^P ≤ 0.001 vs. Veh, by one-way ANOVA with Tukey\'s post hoc tests.Fig. 7

Fluoxetine treatment inhibited weight gain during SD/OC exposure and attenuated weight gain after SD/OC exposure ([Fig. 6](#fig6){ref-type="fig"}). In both trials SD/OC -- Fluoxetine treated mice exhibited a decreased body weight gain during SD/OC exposure relative to SD/OC -- Vehicle (F~(3,\ 43)~ = 9.405, P \< 0.001; [Fig. 7](#fig7){ref-type="fig"}A; F~(3,\ 36)~ = 4.525, P \< 0.01; [Fig. 7](#fig7){ref-type="fig"}D). Over SD/OC and behaviour testing together, SD/OC -- Fluoxetine treated mice exhibited a decreased body weight gain compared to SD/OC -- Vehicle (P \< 0.001; [Fig. 7](#fig7){ref-type="fig"}C; P \< 0.01; [Fig. 7](#fig7){ref-type="fig"}F).

Over SD/OC and behaviour testing together, Cu^II^(atsm) treatment attenuated weight gain compared to SD/OC -- Vehicle in Trial 1 only (P \< 0.01; [Fig. 7](#fig7){ref-type="fig"}C). This was primarily due to decreased weight gain during SD/OC exposure compared to SD/OC -- Vehicle (P \< 0.01; [Fig. 7](#fig7){ref-type="fig"}A) whereas no difference between vehicle and Cu^II^(atsm) treated mice was observed following the SD/OC component during behaviour testing ([Fig. 7](#fig7){ref-type="fig"}B, E). During this period an increase in body weight gain compared to non-SD controls was observed in both trials (P \< 0.001; [Fig. 7](#fig7){ref-type="fig"}B; P \< 0.01; [Fig. 7](#fig7){ref-type="fig"}E), comparable to the increase in weight gain see in vehicle treated mice. Across both trials and all SD/OC groups, the mean weight gain during the 19 day SD/OC component was 0.06 ± 0.01 g/day and during the seven days of behaviour testing was 0.17 ± 0.01 g/day.

All mice exposed to the SD/OC protocol exhibited peaks in weight associated with the days in which they were overcrowded ([Fig. 8](#fig8){ref-type="fig"}A, C). In both trials, all mice exposed to SD/OC exhibited an increased average weight gain across the four OC sessions compared to control mice (F~(3,\ 43)~ = 33.65, P \< 0.001; [Fig. 8](#fig8){ref-type="fig"}B; F~(3,\ 36)~ = 33.65, P \< 0.001; [Fig. 8](#fig8){ref-type="fig"}D), which remained single housed during these periods. Fluoxetine treated mice exhibited a decreased weight gain during OC sessions compared to Cu^II^(atsm) treated mice (P \< 0.05; [Fig. 8](#fig8){ref-type="fig"}B; P \< 0.05; [Fig. 8](#fig8){ref-type="fig"}D), as too did vehicle treated mice for Trial 1 only (P \< 0.01; [Fig. 8](#fig8){ref-type="fig"}B). Across both trials and all SD/OC groups, the mean weight gain during the OC procedures alone was 0.87 ± 0.04 g/day.Fig. 8**Effects of overcrowding procedures on body weight**.Changes in body weight in (**A**) Trial 1 and (**C**) Trial 2. The peaks and troughs in body weight were associated with the overcrowding procedures throughout the SD/OC protocol. Arrowheads represent the intervals in which the mice were overcrowded. Bar graphs show the mean percentage weight gain during the four OC sessions for (**B**) Trial 1 and (**D**) Trial 2. Control mice remained single housed during these periods. Data are means ± SEM. n = 10--12. ^∗∗∗^P ≤ 0.001 vs. Con; ^†^P \< 0.05, ^††^P \< 0.01 vs. Cu(atsm), by one-way ANOVA with Tukey\'s post hoc tests.Fig. 8

3.3. Behaviour {#sec3.3}
--------------

### 3.3.1. SIT {#sec3.3.1}

The SD/OC model did not induce social avoidance behaviour in any of the treatment groups in either trial, in contrast, all treatment groups spent significantly more time in the interaction zone with the 'target' present compared with their respective trial with 'no target' present (Control: P \< 0.001, SD/OC -- Vehicle: P \< 0.001, SD/OC -- Fluoxetine: P = 0.0082, SD/OC-Cu^II^(atsm): P \< 0.001; [Fig. 9](#fig9){ref-type="fig"}A; Control: P = 0.0004, SD/OC -- Vehicle: P = 0.0003, SD/OC -- Fluoxetine: P = 0.0059, SD/OC-Cu^II^(atsm): P = 0.0009; [Fig. 9](#fig9){ref-type="fig"}C). Furthermore, in Trial 1 SD/OC-Cu^II^(atsm) mice exhibited a higher interaction ratio as compared to controls (F~(3,\ 42)~ = 6.197, P \< 0.05; [Fig. 9](#fig9){ref-type="fig"}B).Fig. 9**Effects of SD/OC on social avoidance behaviour**.Social avoidance behaviour in the social interaction test on day 20 of testing in (**A, B**) Trial 1 and (**C, D**) Trial 2. Data are (**A, C**) time spent in the interaction zone (IZ) with 'no target' and 'target' and (**B, D**) the interaction ratio (time spent in IZ with 'target' present \[s\]/time spent in IZ with 'no target' present \[s\]) for Trial 1 and 2 respectively. Data are means ± SEM. n = 10--12. ^\#\#^P ≤ 0.01, ^\#\#\#^P ≤ 0.001 vs. 'no target' trial, by Student\'s paired *t*-test; ^∗^P ≤ 0.05 vs. control, by one-way ANOVA with Tukey\'s post hoc tests.Fig. 9

### 3.3.2. LMA {#sec3.3.2}

No significant difference in the distance travelled (Supp [Fig. 1](#fig1){ref-type="fig"}A, E) was observed between groups in either Trial 1 or 2.

### 3.3.3. LDB {#sec3.3.3}

Compared to controls, mice exhibiting anxiety related behaviour were expected to spend less time in the light side of the arena and to make fewer transitions from the dark to light side. SD/OC -- Fluoxetine treated mice spent significantly less time in the light area in both trials (F~(3,\ 43)~ = 5.164, P \< 0.01 vs. control; P \< 0.05 vs. SD/OC -- Vehicle; Supp [Fig. 1](#fig1){ref-type="fig"}B; F~(3,\ 36)~ = 3.254, P \< 0.05 vs. control; Supp [Fig. 1](#fig1){ref-type="fig"}F). No significant differences were observed for the number of light-dark transitions (data not shown) between groups in either trial.

### 3.3.4. SPT and FST {#sec3.3.4}

No significant difference in saccharin preference was observed in the SPT between groups (Supp [Fig. 1](#fig1){ref-type="fig"}C, G). Furthermore, no alterations in immobility time between the groups were seen in the FST in either Trial 1 or 2 (Supp [Fig. 1](#fig1){ref-type="fig"}D, H).

4. Discussion {#sec4}
=============

The aims of this study were to evaluate the influence of the SD/OC protocol on the behaviour and body weight of mice, and to further characterise the effects of the antidepressant fluoxetine and copper BTSC compound Cu^II^(atsm) in this model. The principle finding was a reproducible and consistent increase in body weight in mice exposed to the SD/OC protocol, and particularly during OC sessions. Both drug treatments investigated reduced chronic weight gain, but not during OC sessions. In Trial 2 a small effect of fluoxetine on defeat postures was detected during the SD phase, however, the SD/OC model otherwise failed to induce depression- or anxiety-like behaviour in two independent cohorts of mice across a range of behavioural tests, despite the increased aggression administered from Trial 1 to Trial 2.

Social defeat models have been utilised in an attempt to elicit depression/anxiety related etiology with varying degrees of success. Avoidance behaviour following social defeat models is a key behavioural outcome thought to signify social withdrawal ([@bib9]) and is a common symptom in people with depression ([@bib10]; [@bib18]). A 10 day social defeat model (SD10) described by [@bib19] produced significant social avoidance behaviour ([@bib6]; [@bib34]; [@bib77]; [@bib78]). However, a concern of this model is the elevated risk of injuries and potentially confounding peripheral inflammation ([@bib19]; [@bib61]). The SD/OC model has a shorter SD interaction time therefore reducing the opportunity for injuries to occur, and has also been reported to produce social avoidance behaviour in some ([@bib13], [@bib14]; [@bib76]), but not all studies ([@bib74]). Social avoidance behaviour, however, was not observed in the current experiments, despite escalating levels of aggression across the two trials -- the reasons for this are unclear. [@bib34] subjected 437 C57BL/6 J mice to the SD10 protocol and identified susceptible and unsusceptible subpopulations of responders, with 40--50% of defeated mice showing a preference for interacting with a social target, similar to non-defeated controls. In the present investigation, however, across both trials, none of the 22 vehicle treated C57BL/6JArc mice and only three of the total 65 mice exposed to the SD/OC model exhibited a social interaction ratio of less than one. Differences in the behaviour of substrains of C57BL/6 strains have been reported previously ([@bib48]). However, the C57BL/6JArc mice used in the present study were found to be identical to C57BL/6 J from both Jackson (as used in the study by [@bib34]) and Charles River laboratories at 1449 single nucleotide polymorphisms in a linkage mapping panel ([@bib85]). This suggests that substrain genetic differences alone are unlikely to have been a major factor in the resilience seen in intruder mice used in the present study.

It is possible that despite the two escalating levels administered, aggression levels may have been insufficient to produce avoidance or depression-like behaviours in the present study. To date, however, the quantification of injuries, the number of defeat postures and attacks, or aggression intensity are sparsely reported in the literature, making comparisons between models challenging. To address this, we sought to quantify the number of defeat postures expressed per mouse, in order to determine if increasing defeat postures related to subsequent depression-related behaviours. In Trial 1, defeat postures were limited to one display before cessation of SD bouts. We aimed to limit defeat postures to five in the second trial, although the speed with which defeat postures were displayed made precise bout termination challenging, and as a result more defeat postures were commonly displayed. This indicated that intruders were aware of the increased aggression level between trials and responded accordingly. Furthermore, in Trial 2 the number of defeat postures increased with SD sessions, with experimental mice also showing a marked reduction in latency to defeat posture over the first four, but not subsequent sessions. Interestingly, this appeared to be somewhat unrelated to the attack latency of aggressors over the thirteen SD sessions, which was remarkably stable across the entire study. The consistent behaviour of the aggressors also failed to explain the increasing number of defeat postures displayed by intruders over the course of the SD/OC protocol. Within sessions, however, latencies to attack or to show defeat posture in aggressors and intruders respectively, were shorter in the second, post-barrier bouts, indicating the 2 h non-contact exposure effectively intensified aggressive interactions and responses to them. Whether shortened latency to, and increasing number of, defeat postures are evidence of depression-like behaviour or a learned defense mechanism remains to be determined, although the lack of depression-related responses following SD/OC suggests they may primarily represent the latter. However, defeat postures, although largely unaffected by drug treatment, were reduced in fluoxetine-treated mice on three of the 26 SD bouts, suggesting that some contribution from underlying depression-like mechanisms cannot be ruled out.

The specific strain of aggressor mouse used may be a vital aspect of social defeat models. In previous studies employing either the SD/OC or SD10 models, CD1 mice were commonly selected as the aggressors. In screening and Trial 1 of the present study a mixture of strains was utilised and revealed aggression differences amongst them, particularly latency to attack. SJL mice displayed high levels of unprovoked aggression in screening and throughout all SD sessions, reliably exhibiting attack latencies of \<5--10 s. This strain is noted for a high expression of aggression and fighting when group housed ([@bib8]; [@bib58]). Of the 29 SJL mice screened only one exhibited low levels of aggression. On the other hand, Golden et al. (2011) reported that up to half of the screened CD1 mice did not meet the appropriate aggression criteria, a finding confirmed in the present study. The aggression of SJLs, as assessed by attack latency, therefore seems to be an unlikely reason for the lack of depressive-like or social avoidance behaviour observed in intruders. Alternatively, the style of attack may be an important variant in promoting depressive-like behaviour. Subjectively, we observed that Swiss and CD1 mice commonly enveloped the smaller C57BL/6JArc mouse when fighting, using their greater size to their advantage. Bite wounds in these SDs were uncommon. Contrarily, the SJL mice, of comparable size to the C57BL/6JArc mice, exhibited swift, 'ambush style' attacks, unexpectedly pouncing at or on the C57BL/6JArc mouse. Bites to the lower back and tail were delivered -- typically during running/chasing. Interestingly, this type of aggressive behaviour, despite the reliable ferocity, did not result in avoidance of SJL mice in the SIT. Nor did it result in depressive-like behaviour overall, despite potential conflicts from bite wounds. These data suggest that aggression, defined as attack latency alone, is insufficient to capture the factors required to induce social avoidance behaviour. The precise characteristics of resident aggression that promotes social avoidance behaviour thus remains to be fully determined. Future experiments comparing the aggression style of SJL versus CD1 mice on the behavioural outcomes of victims may therefore prove enlightening. Including the assessment of stress hormone levels in intruders in response to the different styles and levels of aggression of specific aggressor strains would be a valuable addition to such a study.

A main finding of the present study was a consistent increase in body weight in response to the SD/OC protocol. Major alterations in eating patterns and body weight are a common occurrence amongst depressed, anxious or stressed people ([@bib33]; [@bib42]; [@bib57]). In the present study, SD stress increased body weight during the SD/OC component, and even more so in the week following stressor exposure. It should be noted that all mice in this study received oral gavage daily, which could have represented an additional stressor. This may have contributed to a slightly lower weight gain in the control (vehicle-treated, no SD/OC) mice (∼4.5%) than expected from reference growth rates (∼11%; [@bib29]). This amounts to a difference in weight change of ∼0.038 g/day across the 26-day protocol and variations in mice and laboratory conditions could explain this. However, repeated oral gavage performed correctly is not particularly stressful for mice ([@bib2]) in comparison with intraperitoneal (IP) injection, as assessed by adrenocorticotropic hormone (ACTH) and cortisol responses ([@bib3]). Furthermore, a number of SD studies have used repeated IP injections for 28--30 days ([@bib4]; [@bib6]; [@bib77]; [@bib78]) and compromise in weight gain in control mice was not noted in these studies. However, if gavage stress diminished weight gain in the present study, it was controlled for to some degree, since all SD/OC mice also received the same gavage stress and increases in weight relative to the control group were still observed.

In humans, body weight changes in response to stress and/or depression can progress in opposite extremes -- substantial increases in food intake and weight are quite common although, lack of appetite and decreased weight are also observed ([@bib75]; [@bib80]). Similarly, weight changes in mice exposed to social defeat paradigms are varied. As in the present study, increases in weight during the SD/OC protocol have been previously observed ([@bib14]; [@bib76]). However, [@bib66] reported a decreased weight gain as compared to controls during the 19 day protocol whilst [@bib13] observed a decrease in body weight in mice on a high-fat diet whereas mice on a low-fat diet exhibited no change. [@bib74] found no difference in weight during stressor exposure but observed an increase in weight following stressor cessation. In another social defeat model, [@bib69] found a less intense protocol (more closely resembling SD/OC) resulted in an increase in weight gain whereas the more intense model (more closely resembling SD10) resulted in no change as compared to controls ([@bib69]). [@bib20] also observed an increase in weight gain when employing a less intense version of the SD10 model. Two separate studies found no alteration in weight during the 10 days of defeat but a substantial increase in weight following stressor termination ([@bib78], [@bib79]). [@bib70] reported a decrease in weight during their social defeat protocol as did [@bib34]. Although these studies show divergent bodyweight changes during social defeat procedures, weight gain following stressor termination is more consistently reported ([@bib52]; [@bib63]; [@bib74]), in agreement with the findings from this study. This was postulated to be a protective mechanism to prepare the body for potential future stressors ([@bib74]).

Specific peaks in weight gain were observed in both present trials which were tightly associated with the overcrowding procedure. During OC sessions defeated mice averaged a body weight increase of 0.87 g per day, a striking difference to the typical male C57BL/6 J growth rate of 0.13 g per day ([@bib29]). As previously reported ([@bib74]), a large increase in weight gain was also seen in the present study in the one week period following SD termination however, these only reached a mean of 0.17 g per day (albeit blunted by the protective effects of fluoxetine/Cu^II^(atsm)). The magnitude and rapidity of weight gain and subsequent loss associated with OC sessions suggest a transient hyperphagia. This raises interesting questions regarding the role of the overcrowding procedure as a social stressor. Binge eating was recently recognized as a distinct eating disorder in the DSM V ([@bib1]), and is associated, amongst other psychiatric disorders, with depression, as well as stress and social distress ([@bib31]; reviewed in [@bib64]; [@bib65]). Furthermore, hyperphagia, obesity and insulin resistance have been previously reported in animal models of chronic social defeat ([@bib31]; [@bib65], [@bib64]). The acute peaks in weight gain caused by OC may pinpoint binge eating behaviour to an acute, defined, social challenge point within the SD/OC model. It is also of interest that neither fluoxetine nor Cu^II^(atsm) attenuated the transient weight gain during OC, perhaps reflective of the findings in humans where selective serotonin re-uptake inhibitors (SSRIs) show limited efficacy for the treatment of binge eating ([@bib16]). OC-induced transient weight gain thus bears further investigation to define underlying neurobiological correlates of relevance to the study of stress-induced binge eating.

Weight gain during the 19 day SD/OC component of the protocol was prevented by fluoxetine whilst Cu^II^(atsm) attenuated it, a finding replicated across both trials. A number of studies have associated antidepressant treatment such as fluoxetine with inhibition of weight gain in humans ([@bib22]; [@bib38]; [@bib53]; [@bib72]) and in rodents ([@bib21]; [@bib39]; [@bib83]) however, the neurobiological processes behind these changes are not well understood ([@bib36]). Fluoxetine has been reported to decrease weight gain even in unstressed mice ([@bib84]), and as such may have had direct effects on bodyweight in the present study that were independent of its anti-depressant properties. However, no such effect was observed with Cu^II^(atsm) dosed in non-transgenic C57BL/6 J x C3H/HeJ mice up to 60 mg/kg/day for more than 200 days ([@bib49]). This is, therefore, the first time that attenuation of stress-induced weight gain has been demonstrated using Cu^II^(atsm) and these data may thus suggest a different mechanism of action between the two compounds in this regard. It also provides support for further investigations into the association between nitrosative stress and aspects of depression such as weight gain ([@bib40]; [@bib45]).

Despite changes in body weight, SD/OC otherwise failed to elicit depression related behaviour. These results are in agreement with those found by [@bib74] who observed no difference in saccharin preference in the SPT, nor immobility time in either the FST or TST following SD/OC. An increase in anxiety-like behaviour was observed in the EPM although this reached significance only nine days after cessation of the SD/OC model ([@bib74]). A main conclusion of that study was that the SD/OC model induced an anxiogenic, but not depressive, response which only arose in the week following stressor termination ([@bib74]). In the present study, however, anxiety-related behaviour in the LDB was not influenced by SD/OC as assessed three days after stressor termination. In contrast, [@bib13] observed a significant decrease in the time spent in the light side of the LDB as well as an increase in immobility time in the FST when compared to controls. However, both these effects were only present in mice on a low fat diet. The finding that chronic fluoxetine treatment did not reduce immobility in the FST in SD/OC mice was unexpected, however, [@bib78] observed male C57BL/6 mice exposed to chronic social defeat stress exhibited an increased immobility time compared to controls but this was not altered by fluoxetine treatment, whereas venlafaxine significantly reduced immobility time. Furthermore, it has been reported that C57BL/6 mice are not particularly sensitive to fluoxetine treatment in the FST ([@bib41]). Together these data suggest that either noradrenergic may be more involved than serotonergic mechanisms in response to SD/OC, or alternatively, that C57BL/6 mice may not be the ideal strain to investigate serotonergic mechanisms in social defeat ([@bib30]).

In conclusion, a key aim of this study was to further explore the SD/OC protocol as an etiological animal model of depression; however, depression-like behaviours were not observed in two independent trials with different levels of aggression. The reliable reproduction of complex stress models on depressive-like behaviour remains a focal point for the field, as has recently been highlighted with the related model; CMS ([@bib82]). In [@bib82] investigation few, if any, differences were identified between laboratories that reliably reproduced the CMS model versus those which did not. Nevertheless, possible reasons for reproducibility issues discussed therein included differences in individual experimenters, experimental subjects, stress susceptibility of strains, variation within strains, accuracy of outcomes measures and the severity of stress. We have addressed substrain susceptibility of intruders, severity of stress and individual variations within intruders in the context of the present study. We also identified the importance of the strain and aggression style of resident mice as a possible source of variation, which further research may ultimately prove a valuable discovery tool within SD models. Other factors identified by [@bib82] may also have played a role in the results of the present study, as in previous studies. However, coupled with comparable results obtained from another study ([@bib74]) these experiments raise concerns over the reproducibility of the SD/OC protocol as an etiological model of depression across laboratories. Appropriate reporting regarding SD protocols, levels of aggression delivered and responses of victims thereto may prove vital in overcoming issues associated with variability in social defeat stress models. Nevertheless, the SD/OC model reliably elicited stress-induced weight gain; a core symptom of depression in humans. Chronic fluoxetine treatment reversed, and Cu^II^(atsm) attenuated this weight gain, pointing to underlying serotoninergic and peroxynitrite-related mechanisms. The OC component of the SD/OC model may bear further investigation as a platform to study the neurobiology of social stress-induced weight gain and binge eating -- a prevalent concern of the modern era. These findings highlight the potential of the SD/OC model to investigate factors affecting weight gain following stressor exposure, and to provide a greater understanding of the mechanisms behind these stress-induced changes.
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